Clinical Trial Update: Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years [Phase 1]

View source ↗

Summary

Phase I study of the pneumococcal conjugate vaccine PCV24 in children aged 2 months to 17 years is listed as active but not recruiting, sponsored by Shanghai Re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Disease

Drugs mentioned

• PCV24 (24-valent pneumococcal conjugate vaccine)

Snippet

Sponsor: Shanghai Reinovax Biologics Co.,LTD | Conditions: Pneumococcal Infectious Disease | Phase 1 | Status: ACTIVE_NOT_RECRUITING